TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03284788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABT Weight Loss Intervention
Description: This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.
Study: NCT03278938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion
Description: FDA approved drug for treating depression
Study: NCT02449993

Intervention type: DEVICE
Intervention: MammaTyper™
Description: MammaTyper™ is an in vitro molecular diagnostic test for the quantitative detection of the biomarkers estrogen receptor (ESR1), progesterone receptor ( PgR), Human epidermal growth factor receptor 2 (HER2) and proliferation antigen Ki-67 on the basis of the values of the messenger ribonucleic acid (mRNA).
Study: NCT03278938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion
Description: FDA approved drug for treating depression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: FDA approved treatment for depression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: FDA approved treatment for depression
Study: NCT02641392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301
Description: Mongersen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301
Description: Mongersen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301
Description: Mongersen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301
Description: Mongersen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301
Description: Mongersen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02484157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemochron
Description: Activated coagulation time was checked serially by Hemochron Jr.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACT Plus
Description: Activated coagulation time was checked serially by ACT Plus.
Study: NCT05465057

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training (HIIT) + lifestyle intervention (TCOCT)
Description: The participants randomized for HIIT will perform supervised training sessions three times a week for 3 months. All HIIT programs consist of activities that involve 4 x 4 min. intervals at 90-95% of HRmax.~The lifestyle intervention (TCOCT) comprises a lifestyle intervention targeting all aspects of everyday life, incl. guidance on diet, physical activity, sleep, screen time, and social problems. The participant will be scheduled for follow up in the out-patient clinic or municipal obesity clinic by a trained pediatric nurse and dietician after 6-12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention (TCOCT)
Description: The lifestyle intervention (TCOCT) comprises a lifestyle intervention targeting all aspects of everyday life, incl. guidance on diet, physical activity, sleep, screen time, and social problems. The participant will be scheduled for follow up in the out-patient clinic or municipal obesity clinic by a trained pediatric nurse and dietician after 6-12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention (TCOCT)
Description: The lifestyle intervention (TCOCT) comprises a lifestyle intervention targeting all aspects of everyday life, incl. guidance on diet, physical activity, sleep, screen time, and social problems. The participant will be scheduled for follow up in the out-patient clinic or municipal obesity clinic by a trained pediatric nurse and dietician after 6-12 weeks.
Study: NCT05682911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zingiber officinale L. tablets
Description: Zingiber officinale L. tablets 500mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 20mg
Description: Simvastatin 20mg once a day for 2 months
Study: NCT01484639

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal transfusion triggers
Description: Patients allocated to a liberal transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive transfusion triggers
Description: Patients allocated to a restrictive transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively.
Study: NCT03656601

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D pelvic ultrasound
Description: 3D pelvic ultrasound by transperineal route

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D pelvic ultrasound
Description: 3D pelvic ultrasound by transperineal route

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D pelvic ultrasound
Description: 3D pelvic ultrasound by transperineal route
Study: NCT01298960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: 0.1 IU/Kg/day from day one of stimulation until rHCG triggering
Study: NCT02398929

Intervention type: DRUG
Group type: OTHER
Intervention: Bisoprolol 2.5 mg
Description: Bisoprolol 2.5 mg will be given once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo tablets will be given once daily for 2 weeks during the run-in period.
Study: NCT01312870

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure, Abbott Nutrition
Description: Enteral feeding Ensure, Abbott Nutrition 400 ml per day for seven postoperative days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard hospital diet
Description: standard hospital diet
Study: NCT05159622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water Up! at Home
Description: 1: Addressing physical barriers to replace SSB with water at home: Participants will receive a personal, reusable bottle of water, a National Sanitation Foundation-certified water filter pitcher and one additional filter cartridge 2: Addressing sociocultural barriers to change individual perceptions: The curriculum has 6 topics delivered in 12 sessions: a) water for your health (diabetes/obesity among Latinos); b) health benefits of water vs. SSB, c) sugar content of SSB, d) safety \& affordability of filtered tap water vs. bottled beverages, e) access and promotion of SSB vs. water in your community, f) tips for improving water taste, perceived susceptibility, severity, costs and benefits. 3: Addressing sociocultural barriers to increase skills: During each session, participants will be asked to perform hands-on learning activities (e.g., measure sugar content in SSB, take pictures of themselves explaining to their family members the key messages of various lessons).
Study: NCT03434327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: Eleven resistance training exercises performed on pneumatic resistance training machines using 2 second concentric and 3 second eccentric contractions at 75-80% of each subjects maximal strength. Subjects will perform 3 sets per exercise, two times per week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power Training
Description: Eleven resistance training exercises performed on pneumatic resistance training machines using maximum speed concentric and 3 second eccentric contractions at the load that produces the highest power for the individual. Subjects will perform 3 sets per exercise, two times per week for 12 weeks.
Study: NCT02566018

Intervention type: PROCEDURE
Intervention: treatment/medical device
Description: The new treatment algorithm was applied to all patients with proximal humerus fracture as from May 2013 onwards

Intervention type: PROCEDURE
Intervention: standard
Description: The old treatment algorithm was applied to all patients with proximal humerus fracture up to May 2013.
Study: NCT01440400

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided spinal anesthesia
Description: Using the ultrasound to identify the spinal puncture level, mid-line and the depth of the dura.
Study: NCT02450331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 milligrams (mg).
Study: NCT02178605

Intervention type: PROCEDURE
Intervention: Cervical arthrodesis with rhBMP-2
Description: Cervical arthrodesis with rhBMP-2
Study: NCT01410474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY conjugate vaccine
Description: All subjects received a single dose of Meningococcal ACWY conjugate vaccine and had blood draw at day 1 and day 29.
Study: NCT04481295

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal cannula
Description: The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low SpO2
Description: Low SpO2
Study: NCT01608009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib and paclitaxel
Description: Pazopanib 800mg od for 7 days, followed by 18 weeks of combination therapy (paclitaxel 80mg/m2 weekly and pazopanib 800mg od). Following the completion of combination therapy, patients will continue on maintenance pazopanib 800mg od until disease progression.
Study: NCT02242513

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed radiofrequency (PRF)
Description: Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xylocaine
Study: NCT00033696

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03574493

Intervention type: PROCEDURE
Intervention: TME with LAR
Description: Several surgical techniques are used to perform TME. Dissection using open laparotomy and minimally-invasive laparoscopic or robot-assisted abdominal approaches is performed in a 'top-down' manner, where the instruments are inserted transabdominally and the procedure progresses from splenic flexure/sigmoid colon mobilization to rectal resection. A transanal approach may also be used, a 'bottom-up' procedure where instruments are inserted through the anus to perform rectal resection and TME

Intervention type: PROCEDURE
Intervention: TME with LAR
Description: Several surgical techniques are used to perform TME. Dissection using open laparotomy and minimally-invasive laparoscopic or robot-assisted abdominal approaches is performed in a 'top-down' manner, where the instruments are inserted transabdominally and the procedure progresses from splenic flexure/sigmoid colon mobilization to rectal resection. A transanal approach may also be used, a 'bottom-up' procedure where instruments are inserted through the anus to perform rectal resection and TME
Study: NCT02233179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removable cast walker
Description: Offloading device that can be removed by patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irremovable cast walker
Description: Offloading device that cannot be removed by patients.
Study: NCT04023279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS
Description: 100 Hz and 100 usec for 20 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS
Description: 100 Hz and 100 usec for 20 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial therapy
Description: Seven to fifteen transverse sliding repetitions and three repetitions of longitudinal sliding of myofascial release therapy
Study: NCT03965312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous temperature monitor
Description: Temperature will be measured using a novel temperature monitor continuously for up to 72 hours. Accuracy (as compared to a commercially available patient monitor) will be evaluated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neonatal Incubator
Description: Infants at risk for hypothermia will be placed in a neonatal incubator. Their temperature will be monitored as they are treated. The infant will be treated until the infant is transitioned to skin-to-skin care, discharged, or no longer at risk for hypothermia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient monitor
Description: Temperature will be measured using a commercially available patient monitor.
Study: NCT02789007

Intervention type: OTHER
Group type: OTHER
Intervention: Assess the impact of parabolic flight
Description: MRI testing will be performed using a 3T MRI facility in Bordeaux close to Novespace (CHU Pellegrin).~Spatial cognition will be assessed using a battery of in-house virtual paradigms General cognitive performance testing will include a wide range of cognitive functions, and particularly executive control using the Cognition Battery Mental status will be assessed on a tablet computer using a visual analogue scale Vigilant attention will be determined using the 3-min Psychomotor Vigilance Test (PVT) Blood samples (5 mL per collection) will be collected prior to neuroimaging by venepuncture
Study: NCT04893148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IGlarLixi
Description: Changing to iGlarLixi from insulin glargine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Add dulaglutide to insulin glargine
Study: NCT02489396

Intervention type: BEHAVIORAL
Intervention: Nutrition facts automatically or not automatically displayed
Description: For two months nutrition information on the Rosie site will be displayed in a tab that consumers can click on to display the nutrition facts panels of products. Investigators will use NuVal scores to determine the fifteen healthiest, and fifteen least healthy items in six grocery categories; chips, cookies, cereal \& breakfast, yogurt, ice cream, and frozen pizza. We will then compare the number of clicks on nutrition information for healthier versus less healthy items to determine if there's a possibility of willful ignorance coming into play when choosing to purchase less healthy items.

Intervention type: BEHAVIORAL
Intervention: Nutrition facts in color
Description: For two months the font on products' nutrition facts labels will be displayed in red or green. For this proof-of-concept intervention, the color of a label's display will be determined randomly, in order to gather a clearer picture of whether label color could be leveraged to influence product choice. Items in each grocery category will be randomly assigned to receive green or red labels during the intervention period, so 50% of products in each category have red nutrition facts labels, and 50% have green nutrition facts labels. We will then compare proportions of green to red items purchased during the intervention period with the proportion of those same items purchased during the baseline period, when all labels were in black font.

Intervention type: BEHAVIORAL
Intervention: Nutrition Facts Label in Larger Font
Description: For two months the serving size and calorie lines on the nutrition facts labels will be displayed in a larger font for every item on the Rosie site. Average calories in customer purchases will be quantified using purchase data, and the average calories for online-grocery orders during baseline and intervention periods will be compared.

Intervention type: BEHAVIORAL
Intervention: Healthier Items First
Description: For two months, instead of the product popularity default-display option in the online store, thirty healthier items will be displayed on the first page in each grocery category. All grocery categories where there is scoring variation between healthy and less-healthy options (i.e. cereal, chips, bakery, sauces, etc.) will be included in the intervention. The thirty-targeted healthy items will be identified using NuVal scores. NuVal scores will not actually be displayed as part of the shopping site, and will be used exclusively as a guide to systematically determine targeted items in each food category. The proportion of targeted healthy items purchased in each category versus non-targeted items purchased during the intervention will be compared to the proportion of targeted vs. non-targeted items purchased during the baseline period.
Study: NCT01118533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: metal reusable blades MacIntosh
Description: laryngoscope blades

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single use plastic blades HEINE XP®
Description: laryngoscope blades
Study: NCT04274920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bioactive Glass
Description: Bioactive glass was incorporated in resin composite and its adhesive

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light cured calcium hydroxide
Description: Light cured calcium hydroxide
Study: NCT04499573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19/CD22 CAR-T
Description: The treatment plan will be based on stratification by the initial leukemia burden.~Patients with low disease burden will receive a lymphodepletion chemotherapy of fludarabine (total dose 120mg/m2) and cyclophosphamide (total dose 750mg/m2) over 5 days.~Patients will high disease burden will receive a lymphodepletion chemotherapy of fludarabine (total dose 120 mg/m2), cyclophosphamide (total dose 750 mg/m2), cytarabine (total dose 900 mg/m2), etoposide (total dose 450 mg/m2), dexamethasone (total dose 30 mg/m2) over 5 days.~Based on interim analysis the following dosing approach will be implemented starting April 2021:~Cohort 1: CD19+ disease, low and high burden: 1st dose - 150k/kg, 2nd dose - 850k/kg Cohort 2: CD19- disease, low and high burden: 1st dose - 500k/kg, 2nd dose - 500k/kg Cohort 3: HSCT+CAR-T: 100k/kg
Study: NCT03384173

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: Application of regional NIRS sensors to brain and kidney sites in the first 48 hours after birth to monitor regional tissue oxygenation for the first 7 days of age.
Study: NCT01919268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrotherapy
Description: Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of Pilates method will be individualized to each patient's needs (pragmatic treatment).
Study: NCT04710082

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photorefractive keratectomy (PRK)
Description: Photorefractive keratectomy (PRK) is a surgical procedure used by ophthalmic surgeons to treat patients presented with refractive errors and involves corneal epithelial removal followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photorefractive keratectomy (PRK)
Description: Photorefractive keratectomy (PRK) is a surgical procedure used by ophthalmic surgeons to treat patients presented with refractive errors and involves corneal epithelial removal followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.
Study: NCT04638998

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: MRSI is a non invasive imaging technique used to detect neuroinflammation.

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: MRSI is a non invasive imaging technique used to detect neuroinflammation.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood will be drawn to assess systemic inflammation in Gulf War verterans.
Study: NCT01919268

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pilates
Description: Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
Study: NCT02257489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: recombinant fusion protein
Study: NCT04638998

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood will be drawn to assess systemic inflammation in Gulf War verterans.
Study: NCT00002587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study: NCT05506787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02258139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B&L Investigational Contact Lens
Description: The lens used in this study will be supplied by the Sponsor. All subjects will wear a -3.00D lens.
Study: NCT06222515

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: 3-day bladder diary record including fluid intake, urine amount, urgency and incontinence.
Study: NCT03232983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014 (SC)
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014 (SC)
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014 (SC)
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY900014 (IV)
Description: Administered IV
Study: NCT02257489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: recombinant fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: recombinant fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: recombinant fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: recombinant fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: recombinant fusion protein